
Investment arm of Rabobank backing early-stage Dutch and global food and agriculture companies

Early-stage venture fund taking science and engineering research from labs to market

Early-stage investment in science and engineering is the work of ATP Fund, which partners with inventors who are turning research into products. The fund works with innovators from national laboratories, universities and corporate research groups, and it presents its aim as closing the gap between a laboratory idea and a market, which it calls the research-to-development problem.
The fund concentrates on pre-seed, seed and Series A financing, with particular emphasis on the early stages where research is translated into a company. It describes its work as a marketplace approach to innovation, meant to benefit society while producing sustainable economics for its investors and other stakeholders.
ATP brings together four groups that it says make up the research-to-development ecosystem: innovators, entrepreneurs, investment partners and corporations. Entrepreneurs include first-time founders and seasoned executives. Investment partners are top-tier venture firms and the fund's own syndication networks, and corporations are included so that demand meets supply.
To support its companies the fund runs a program it calls Proto.n, an acceleration process that adds to the resources available to each portfolio company. The firm also describes a curated pipeline of ventures at the intersection of computing and carbon, and an approach to due diligence in which mission-aligned co-investors review each opportunity together.
The fund's themes cover emerging research in deep tech, including therapeutics, diagnostics and treatment delivery aimed at better health outcomes. They also cover systems approaches to a connected world, focusing on resilience and sustainability, and the workforce effects of machine learning and AI. Quantum and distributed ledger technology are also named, with their impact on information security.
ATP says that research funded at American and Canadian universities is under-used by traditional venture capital, and that early-stage venture has outperformed other forms of investment. It reports six exits from its first fund, five sales to acquirers and one listing via a SPAC, and it names economic development in underserved regions and gender access to capital among its target impacts.
ATP Fund is an early-stage venture fund that partners with inventors turning research into products. It describes its aim as solving the research-to-development gap, getting ideas out of the lab and into the market, and it works with a stated focus on outcomes.
It works with researchers, first-time and experienced entrepreneurs, and corporate partners. Its impact themes cover deep tech, health, and resilient, sustainable systems, with attention to underserved regions and gender access.
Summary written by TrustList from the business's own published information, Nov 2026.
2 images - click to enlarge
No questions yet. Be the first to ask about ATP Fund.
Similar listings buyers compare against this one.

Investment arm of Rabobank backing early-stage Dutch and global food and agriculture companies

A growth equity investor in European and US software and technology companies

Investment arm of Liberty Global holding stakes in technology, media, infrastructure and services companies

Early-stage venture investor backing founders with technology-led ideas, with a portfolio across consumer and deep tech

Investment firm backing cannabinoid businesses and publishing research on cannabis consumer markets

Early-stage venture capital firm backing German technology companies as they grow internationally

Series A venture firm backing European technology founders with hands-on support

Venture capital firm backing technology companies across cloud, AI, networking, data and consumer sectors
Everything here links back to the same verified catalogue. Pick your next stop.